Loading
Nanoparticle-based Drug Delivery · Journal article
Acs Applied Materials & Interfaces · August 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage materials engineering study demonstrating proof-of-concept for a magnetic and temperature-responsive hydrogel with folic acid targeting, achieving controlled pulsatile release of 5-fluorouracil and synergistic cytotoxicity in two cancer cell lines in vitro. The work establishes mechanical and biocompatibility properties suitable for further development but provides no evidence of efficacy or safety in vivo or in human subjects.
In vitro materials science study with biocompatibility and cell viability assays. L929 mouse fibroblasts (for biocompatibility), human lung adenocarcinoma cells (NCI-H1975), and fibroblast-like osteosarcoma cells (MG-63) cultured in vitro; no in vivo model or human subjects.. Intervention: UV-crosslinkable and thermo-responsive gelatin methacrylate (GelMa)-poly(N-isopropylacrylamide) (PNIPAM) hybrid hydrogel integrated with folic acid-functionalized superparamagnetic iron oxide nanoparticles (SPIONs), loaded with 5-fluoroura…. Compared with: Pure GelMa and pure PNIPAM hydrogels (for mechanical property comparison); untreated cancer cells (for cytotoxicity comparison)..
2.5G/P hydrogel achieved compressive strength of 0.06 MPa at 78% strain, superior to pure GelMa (0.023 MPa) and PNIPAM (0.012 MPa) L929 fibroblast viability exceeded 70% over 7 days, indicating cytocompatibility Hemolysis ratio below 2%, complying with ISO 10993-4 standards
No in vivo efficacy, pharmacokinetics, biodistribution, or toxicology data reported.
This material platform is at an exploratory stage and has not yet been tested in animal models or humans. Clinicians and translational researchers should view this as early preclinical work that may inform future drug delivery device development, but substantial additional studies—including bioavailability, pharmacokinetics, efficacy, and safety in vivo—are required before any clinical application can be considered.
In vitro proof-of-concept study of a novel hydrogel material platform with demonstrated drug release and cancer cell cytotoxicity, but no animal or clinical data; requires substantial further development before clinical relevance can be assessed.
As stated by the source record.
Quoted from the source exactly as published.
This material platform is at an exploratory stage and has not yet been tested in animal models or humans. Clinicians and translational researchers should view this as early preclinical work that may inform future drug delivery device development, but substantial additional studies—including bioavailability, pharmacokinetics, efficacy, and safety in vivo—are required before any clinical application can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Targeted and on-demand drug delivery technologies have attracted considerable interest for personalized cancer therapies. In this study, we developed a UV-crosslinkable and thermo-responsive gelatin methacrylate (GelMa)-poly(N-isopropylacrylamide) (PNIPAM) (G/P) hybrid hydrogel, integrated with folic acid-functionalized superparamagnetic iron oxide nanoparticles (SPIONs). Differential scanning calorimetry (DSC) and alternating magnetic field (AMF) evaluations confirmed that introducing GelMa modulated the lower critical solution temperature (LCST) to approximately 32 °C while enabling efficient magnetothermal response. Cyclic compression tests demonstrated superior mechanical properties. The 2.5G/P hydrogel achieved a compressive strength of 0.06 MPa at 78% strain, outperforming pure GelMa (0.023 MPa) and PNIPAM (0.012 MPa), with the highest modulus of elasticity at both 25 and 37 °C. In vitro biocompatibility assays using L929 fibroblasts indicated excellent cytocompatibility with >70% viability over 7 days. Furthermore, the hydrogel demonstrated excellent blood compatibility with a hemolysis ratio below 2%, complying with ISO 10993-4 standards. Synergistic reduction in cell viability was observed in human lung adenocarcinoma (NCI-H1975) and fibroblast-like osteosarcoma (MG-63) cell lines when combining drug loading and simulated AMF thermal stimulation. Triggered by hyperthermia at 41 °C, the hydrogel demonstrated a highly controlled, pulsatile 'ON/OFF' drug release profile of 5-fluorouracil (5-FU) driven by network shrinkage, achieving a maximum cumulative release of 72.6% over 28 days with a well-defined biphasic kinetic pattern. These results show that this dual-stimuli responsive hydrogel is a mechanically robust, highly efficient platform for controlled cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.